Clinical Effectiveness and Tolerability of Apremilast in Moderate-to-Severe Plaque Psoriasis: Insights from Real-World Practice Moderate-to-Severe Plaque Psoriasis: Insights from Real-World Practice
Apremilast is an oral phosphodiesterase-4 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Although its efficacy and safety have been demonstrated in randomized controlled trials, real-world data remain limited. This study aimed to evaluate the real-world effectiveness and safety of apremila...